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BACKGROUND & AIMS:

The prevalence and signiﬁcance of digestive manifestations in coronavirus disease 2019
(COVID-19) remain uncertain. We aimed to assess the prevalence, spectrum, severity, and
signiﬁcance of digestive manifestations in patients hospitalized with COVID-19.

METHODS:

Consecutive patients hospitalized with COVID-19 were identiﬁed across a geographically
diverse alliance of medical centers in North America. Data pertaining to baseline characteristics, symptomatology, laboratory assessment, imaging, and endoscopic ﬁndings from the time of
symptom onset until discharge or death were abstracted manually from electronic health records to characterize the prevalence, spectrum, and severity of digestive manifestations.
Regression analyses were performed to evaluate the association between digestive manifestations and severe outcomes related to COVID-19.

RESULTS:

A total of 1992 patients across 36 centers met eligibility criteria and were included. Overall,
53% of patients experienced at least 1 gastrointestinal symptom at any time during their
illness, most commonly diarrhea (34%), nausea (27%), vomiting (16%), and abdominal pain
(11%). In 74% of cases, gastrointestinal symptoms were judged to be mild. In total, 35% of
patients developed an abnormal alanine aminotransferase or total bilirubin level; these were
increased to less than 5 times the upper limit of normal in 77% of cases. After adjusting for
potential confounders, the presence of gastrointestinal symptoms at any time (odds ratio, 0.93;
95% CI, 0.76–1.15) or liver test abnormalities on admission (odds ratio, 1.31; 95% CI, 0.80–
2.12) were not associated independently with mechanical ventilation or death.

CONCLUSIONS:

Among patients hospitalized with COVID-19, gastrointestinal symptoms and liver test abnormalities were common, but the majority were mild and their presence was not associated with
a more severe clinical course.

Keywords: COVID-19; SARS-CoV-2; Digestive Manifestations; Gastrointestinal Symptoms; Hepatic Manifestations.
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ven though coronavirus disease 2019 (COVID-19)
is primarily a respiratory illness, the digestive
system has been implicated in disease expression,
transmission, and possible pathogenesis. The responsible
virus—severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2)—gains cellular entry through the
angiotensin-converting enzyme 2 receptor, which is present in the gastrointestinal tract at higher levels than in
the respiratory system.1–3 Viral RNA has been detected
in the stool of approximately 50% of affected patients,1,4,5 and it has been hypothesized that enteric
infection might modulate the severity of pulmonary
and systemic illness through alterations in the microbiome, dysregulated intestinal immunity, and/or
increased gut permeability.6–8
Digestive manifestations may be common in patients with COVID-19, although reports have been
conﬂicting, and the true prevalence remains uncertain.
Early series from China and 2 recent meta-analyses
suggested that gastrointestinal symptoms occur in
less than 10% of patients,9–13 whereas other studies
have suggested proportions in the range of 30% to
60%.14–17 The prevalence of abnormal liver test results
vary similarly from 15% to 50%.9,12,13,15 More importantly, the signiﬁcance of digestive manifestations in
COVID-19, in terms of impact on the alimentary tract
and liver, and on overall outcomes, is unknown. The
presence and magnitude of gastrointestinal symptoms
and hepatic abnormalities have mirrored disease
severity in some studies, but this observation has been
inconsistent.18–21
Reports on the digestive manifestations of COVID-19
have been limited in scope, reﬂecting the experience of
a single hospital or isolated geographic region, and have
used varying and potentially biased sampling strategies.
We aimed to systematically and rigorously assess the
prevalence, spectrum, and severity of digestive manifestations in consecutive patients hospitalized with
COVID-19 across geographically diverse medical centers
in North America. We also explored the association between the presence of digestive manifestations and
overall outcomes.

E

Methods
Study Design
This was an observational cohort study conducted
through an alliance of 36 medical centers in the United
States and Canada. Any site in North America was eligible
for participation by open invitation. Certain sites were
speciﬁcally invited to maximize geographic, ethnic, and
socioeconomic diversity, and to ensure representation of
regions that were affected disproportionately by the
early phase of the pandemic. Institutional review board
approval was obtained at each center before patient
identiﬁcation and data collection.

Digestive Manifestations in COVID-19 1357

What You Need to Know
Background
Emerging evidence has indicated that gastrointestinal and hepatic manifestations may play an
important role in coronavirus disease 2019 (COVID19), but their prevalence and signiﬁcance remain
uncertain. Two recent meta-analyses showed that
gastrointestinal symptoms occur in less than 10% of
affected patients, whereas other studies have reported rates in the range of 30% to 60%. Similarly,
the prevalence of liver test abnormalities varies from
15% to 50%.
Findings
Using methodology aimed at limiting bias to the
greatest extent possible, we found that gastrointestinal symptoms and liver test abnormalities occurred
in approximately 50% of 1992 patients hospitalized
with COVID-19 across 36 medical centers. These
manifestations, however, were mild in the majority
of cases and their presence was not associated
independently with the need for mechanical ventilation or death.
Implications for patient care
Our ﬁndings afﬁrm that digestive manifestations are
common in COVID-19. However, gastrointestinal
symptoms and liver test abnormalities do not appear
to represent a principal aspect of this disease in
terms of human suffering or resource utilization.
Furthermore, our ﬁndings do not support a strong
association between intestinal severe acute respiratory syndrome coronavirus 2 infection and severe
pulmonary or systemic illness through gut–lung
cross-talk or other mechanisms.

Patients
Adult patients who were hospitalized with a conﬁrmed
diagnosis of COVID-19 according to local real-time polymerase chain reaction testing were considered eligible. To
ensure an unbiased sample, we aimed to enroll the ﬁrst 50
to 100 consecutive patients meeting eligibility criteria at
each participating institution. Potentially eligible patients
were identiﬁed by site investigators using multiple
methods, including but not limited to data warehouse
queries, electronic research subject identiﬁcation tools,
and lists provided by the infectious diseases service or
other relevant hospital entities.

Data Collection and Quality Assurance
Demographic, clinical, laboratory, radiographic, and
endoscopic data from symptom onset until discharge or
death were abstracted manually through review of
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electronic health records by study personnel under the
oversight of a designated clinician investigator. Deidentiﬁed data were entered directly into an electronic data
collection form (Supplementary material; Data Collection
Form). When patients had not been dispositioned by the
end of the study period, data were collected within 3 days
of study closure.
Data quality were ensured to the greatest extent
possible using a 3-tiered system. First, formal instructions
and consistent communications between the data coordinating center and co-investigators emphasized the importance of ensuring response accuracy at the site level and of
seeking clinician investigator input for responses that
required clinical interpretation. In addition, a manual of
procedures for data collection and for the handling of special scenarios (eg, re-admissions or nosocomial infections)
was circulated frequently to the sites throughout the study
period. Second, all incoming data were reviewed manually
by a data manager to identify missing or duplicate data, to
verify that responses were within accepted boundaries, and
to assess for discrepant or conﬂicting responses. Third, data
were reviewed in aggregate by the study team primarily to
assess for inconsistencies and outliers by center. Data concerns prompted direct queries to the sites, and were
resolved before the ﬁnal database freeze.

Deﬁnitions
Digestive manifestations were divided into gastrointestinal symptoms and liver test abnormalities. Because
anorexia is a common and nonspeciﬁc symptom of viral
illness, it was not considered a digestive manifestation in
this study. Similarly, we did not include constipation
because it has not been implicated previously as a symptom of acute or subacute viral infection. Therefore, the
symptoms of interest in this study were diarrhea, nausea,
vomiting, abdominal pain, gastrointestinal bleeding,
dysphagia, and odynophagia. Patients were judged to have
moderate–severe gastrointestinal symptoms when 1 or
more of the following criteria were satisﬁed: (1) diarrhea
with more than 4 bowel movements in any 24-hour
period; (2) bloody diarrhea; (3) hematemesis, melena, or
hematochezia; (4) abdominal computed tomography scan
or endoscopic evaluation was performed; or (5) the
gastroenterology consult service evaluated the patient. All
other patients were considered to have mild symptoms.
Liver test abnormalities were deﬁned as mild when the
alanine aminotransferase level (ALT) or total bilirubin
(TB) level was increased between 1.5 and 3 times the
upper limit of normal, moderate when there was elevation
between 3 and 5 times the upper limit of normal, and
severe at more than 5 times the upper limit of normal.
Liver tests less than 1.5 times the upper limit were
considered normal in this study. The upper limits of
normal for ALT and TB were considered to be 45 U/L and
1.2 mg/dL, respectively. Severe acute liver injury was
deﬁned as an ALT level higher than 1000 U/L, with an
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international normalized ratio greater than 2 or a factor 5
level less than 25%. For descriptive purposes, the proportion of patients with any liver test abnormality is reported, but only ALT and TB increases were used in the
analyses.

Statistical Analysis
Digestive manifestations were reported using
descriptive statistics. Categorical variables were
expressed as counts or percentages with 95% CIs;
continuous variables were expressed as means with SD
or medians with interquartile range (IQR), depending on
distribution. Liver test abnormality proportions were
calculated using the full cohort as the denominator.
The association between digestive manifestations and
the severity of COVID-19 was assessed using a multivariable logistic regression model that included the presence
of gastrointestinal symptoms and liver test abnormalities
as the independent variables of interest and that adjusted
for prespeciﬁed baseline covariates. The primary outcome
was the composite end point of mechanical ventilation
and/or death. Potential covariates that were considered
for the model are listed in the Supplementary material:
Supplementary Table. If a univariable association with the
outcome was observed (P < .10), the covariate was
considered for inclusion in the ﬁnal regression model. We
also explored potential interactions between included
covariates and the primary independent variables. Only
liver tests at admission were assessed because hepatic
injury during critical illness is associated consistently with
multi-organ system failure and death regardless of
etiology.22
In exploratory analyses, the associations between
digestive manifestations and intensive care unit admission, the need for vasopressor support, and hospital
length of stay (modeled as a continuous variable) were
assessed using a similar approach.
All analyses were conducted using SAS 9.4 (SAS
Institute, Inc, Cary, NC). The programming code for the
ﬁnal primary regression model is included in the Supplementary material.
All authors had access to the study data and reviewed
and approved the ﬁnal manuscript.

Results
Patients
From April 15 to June 5, 2020, data were collected
from 1992 subjects across 36 centers. The median
number of patients enrolled per participating institution
was 51 (IQR, 41–68). Characteristics of the study cohort
are shown in Table 1. The average age was 60 years (SD,
16.3 y); 57% were men; and 42% were black/African
American. Eighty-nine percent of patients had at least 1
nondigestive comorbidity, and 9% had a pre-existing

All
(N ¼ 1992)

18–39
(n ¼ 245)

40–49
(n ¼ 270)

50–59
(n ¼ 384)

60–69
(n ¼ 499)

70–79
(n ¼ 358)

80–89
(n ¼ 178)

>89
(n ¼ 58)

60.1 (16.3)
1128 (56.6)

31.2 (6)
130 (53.1)

45.2 (2.9)
175 (64.8)

54.9 (2.7)
223 (58.1)

64.4 (2.9)
294 (58.9)

74.2 (2.9)
195 (54.5)

83.8 (2.9)
86 (48.3)

>89a (NA)
25 (43.1)

864 (43.4)
5 (0.3)

115 (46.9)
1 (0.4)

95 (35.2)
0 (0)

161 (41.9)
2 (0.5)

205 (41.1)
1 (0.2)

163 (45.5)
0 (0)

92 (51.7)
1 (0.6)

33 (56.9)
0 (0)

70 (3.5)

6 (2.4)

11 (4.1)

20 (5.2)

18 (3.6)

10 (2.8)

3 (1.7)

2 (3.4)

Black/African American

842 (42.3)

88 (35.9)

119 (44.1)

167 (43.5)

223 (44.7)

161 (45.1)

68 (38.2)

16 (27.6)

White

732 (36.8)

76 (31)

72 (26.7)

125 (32.6)

186 (37.3)

148 (41.5)

89 (50)

36 (62.1)
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Table 1. Characteristics of the Study Cohort

Demographics
Age, mean (SD)
Sex, n (%)
Race,b n (%)

Male
Female
American Indian/
Alaska Native
Asian

Multiple
Ethnicity, n (%)

Unknown
Hispanic or Latino
Not Hispanic or Latino

Health care worker, n (%)

Unknown
Yes
No

Prior history
Cigarette smoking, n (%)

2 (0.7)

3 (0.8)

2 (0.4)

1 (0.3)

1 (0.6)

332 (16.7)
290 (14.6)

73 (29.8)
71 (29)

66 (24.4)
67 (24.8)

67 (17.4)
52 (13.5)

69 (13.8)
51 (10.2)

37 (10.4)
28 (7.8)

1529 (76.8)

146 (59.6)

176 (65.2)

300 (78.1)

407 (81.6)

301 (84.1)

149 (83.7)

50 (86.2)

173 (8.7)
127 (6.4)

28 (11.4)
26 (10.6)

27 (10)
23 (8.5)

32 (8.3)
41 (10.7)

41 (8.2)
30 (6)

29 (8.1)
3 (0.8)

13 (7.3)
4 (2.2)

3 (5.2)
0 (0)

1653 (83)

187 (76.3)

212 (78.5)

287 (74.7)

410 (82.2)

328 (91.6)

172 (96.6)

57 (98.3)

16 (9)
16 (9)

0 (0)
4 (6.9)
5 (8.6)

212 (10.6)

32 (13.1)

35 (13)

56 (14.6)

59 (11.8)

27 (7.5)

2 (1.1)

1 (1.7)

Current smoker

126 (6.3)

21 (8.6)

15 (5.6)

23 (6)

40 (8)

20 (5.6)

7 (3.9)

0 (0)

Ex-smoker

569 (28.6)

20 (8.2)

37 (13.7)

88 (22.9)

165 (33.1)

151 (42.2)

85 (47.8)

23 (39.7)

1175 (59)

195 (79.6)

201 (74.4)

253 (65.9)

269 (53.9)

161 (45)

71 (39.9)

25 (43.1)

Unknown
Current

122 (6.1)
169 (8.5)

9 (3.7)
26 (10.6)

17 (6.3)
29 (10.7)

20 (5.2)
37 (9.6)

25 (5)
41 (8.2)

26 (7.3)
26 (7.3)

15 (8.4)
6 (3.4)

10 (17.2)
4 (6.9)

Prior

102 (5.1)

7 (2.9)

10 (3.7)

23 (6)

24 (4.8)

24 (6.7)

11 (6.2)

3 (5.2)

No

1500 (75.3)

194 (79.2)

204 (75.6)

283 (73.7)

387 (77.6)

260 (72.6)

131 (73.6)

41 (70.7)

Unknown

221
968
31.5
1
722
1245
435

18
151
35.2
0
50
55
12

27
151
33.6
0
75
121
14

41
205
32.5
1
133
223
55

47
264
31.8
1
221
362
135

48
147
29.1
2
152
280
117

30
46
27.1
2
79
156
74

(11.1)
(48.6)
(8.5)
(0–2)
(36.2)
(62.5)
(21.8)

(7.3)
(61.6)
(10.3)
(0–1)
(20.4)
(22.4)
(4.9)

(10)
(55.9)
(8.9)
(0–1)
(27.8)
(44.8)
(5.2)

(10.7)
(53.4)
(9.3)
(0–2)
(34.6)
(58.1)
(14.3)

(9.4)
(52.9)
(7.5)
(0–3)
(44.3)
(72.5)
(27.1)

(13.4)
(41.1)
(6.2)
(1–3)
(42.5)
(78.2)
(32.7)

(16.9)
(25.8)
(6.4)
(1–3)
(44.4)
(87.6)
(41.6)

10
4
23.9
2
12
48
28

(17.2)
(6.9)
(4.1)
(1–3)
(20.7)
(82.8)
(48.3)
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Obesity, n (%)
Body mass index,c mean (SD)
Charlson Comorbidity Index, median (IQR)
Diabetes, n (%)
Hypertension, n (%)
Cardiac disease, n (%)

1 (0.4)

Unknown

Nonsmoker
Alcoholism, n (%)

10 (0.5)

18–39
(n ¼ 245)

40–49
(n ¼ 270)

50–59
(n ¼ 384)

60–69
(n ¼ 499)

70–79
(n ¼ 358)

80–89
(n ¼ 178)

>89
(n ¼ 58)

414 (20.8)
123 (6.2)

46 (18.8)
6 (2.4)

52 (19.3)
7 (2.6)

74 (19.3)
24 (6.3)

116 (23.2)
42 (8.4)

75 (20.9)
34 (9.5)

40 (22.5)
7 (3.9)

11 (19)
3 (5.2)

265
84
56
55

(13.3)
(4.2)
(2.8)
(2.8)

39
5
2
2

(15.9)
(2)
(0.8)
(0.8)

30
7
8
8

(11.1)
(2.6)
(3)
(3)

59
16
11
14

(15.4)
(4.2)
(2.9)
(3.6)

76
25
15
17

(15.2)
(5)
(3)
(3.4)

51
22
17
10

(14.2)
(6.1)
(4.7)
(2.8)

7
8
3
4

COVID-19 symptoms
Fever (subjective or objective), n (%)
Cough, n (%)
Shortness of breath, n (%)
Fatigue or subjective weakness, n (%)
Myalgia, n (%)

1537
1476
1403
851
580

(77.2)
(74.1)
(70.4)
(42.7)
(29.1)

209
197
186
86
97

(85.3)
(80.4)
(75.9)
(35.1)
(39.6)

222
220
204
105
111

(82.2)
(81.5)
(75.6)
(38.9)
(41.1)

303
301
279
173
127

(78.9)
(78.4)
(72.7)
(45.1)
(33.1)

390
362
359
216
141

(78.2)
(72.5)
(71.9)
(43.3)
(28.3)

254
248
232
167
73

(70.9)
(69.3)
(64.8)
(46.6)
(20.4)

COVID-19 treatments
Hydroxychloroquine/chloroquine, n (%)
Remdesivir, n (%)
Convalescent plasma, n (%)
Glucocorticoids, n (%)
Tocilizumab, n (%)

1036
109
37
240
109

(52)
(5.5)
(1.9)
(12)
(5.5)

115
13
4
23
19

(46.9)
(5.3)
(1.6)
(9.4)
(7.8)

137
20
4
31
16

(50.7)
(7.4)
(1.5)
(11.5)
(5.9)

207
21
9
39
25

(53.9)
(5.5)
(2.3)
(10.2)
(6.5)

280
37
11
69
32

(56.1)
(7.4)
(2.2)
(13.8)
(6.4)

185
9
7
54
9

COVID-19 outcomes
Hospital length of stay, d, median (IQR)
Intensive care unit admission, n (%)
Mechanical ventilation, n (%)
Vasopressor support, n (%)
Death, n (%)

9
878
646
546
375

(4.17)
(44.1)
(32.4)
(27.4)
(18.8)

6
80
53
40
16

(3.11)
(32.7)
(21.6)
(16.3)
(6.5)

7
101
77
58
20

(4.15)
(37.4)
(28.5)
(21.5)
(7.4

8
157
113
94
44

(4.17)
(40.9)
(29.4)
(24.5)
(11.5)

11
269
211
179
93

(5.23)
(53.9)
(42.3)
(35.9)
(18.6)

10
178
134
125
102

Pulmonary disease, n (%)
Active/current malignancy, excluding
nonmelanoma skin cancer, n (%)
Immunocompromised, n (%)
Luminal gastrointestinal disease (nonmalignant), n (%)
Pancreaticobiliary disease, n (%)
Chronic liver disease, n (%)

COVID-19, coronavirus disease 2019; IQR, interquartile range; NA, not available; SD, standard deviation.
a
Age was not collected for patients older than 89 years old.
b
There was 1 missing.
c
There were 172 missing.

(3.9)
(4.5)
(1.7)
(2.2)

3
1
0
0

(5.2)
(1.7)
(0)
(0)

122
112
113
77
24

(68.5)
(62.9)
(63.5)
(43.3)
(13.5)

37
36
30
27
7

(63.8)
(62.1)
(51.7)
(46.6)
(12.1)

(51.7)
(2.5)
(2)
(15.1)
(2.5)

95
7
2
22
7

(53.4)
(3.9)
(1.1)
(12.4)
(3.9)

17
2
0
2
1

(29.3)
(3.4)
(0)
(3.4)
(1.7)

(6.19)
(49.7)
(37.4)
(34.9)
(28.5)

10.5
74
52
44
66

(6.18)
(41.6)
(29.2)
(24.7)
(37.1)

8
19
6
6
34

(5.14)
(32.8)
(10.3)
(10.3)
(58.6)
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Figure 1. Gastrointestinal symptoms in patients hospitalized with coronavirus disease 2019 (COVID-19).

digestive disorder. Thirty-two percent of patients
required mechanical ventilation and 19% died. The median hospital length of stay was 9 days (IQR, 4–17 d).
Thirty patients (1.5%) still were hospitalized at the end
of the study period.

Prevalence, Spectrum, and Severity of
Gastrointestinal Symptoms
Overall, 1052 patients (53%; 95% CI, 51%–55%)
experienced at least 1 gastrointestinal symptom at any
time during their illness (Figure 1). Of these, 227 patients

(11%; 95% CI, 10%–13%) experienced 3 or more
gastrointestinal symptoms. The most common symptoms
were diarrhea (34%; 95% CI, 32%–36%), nausea (27%;
95% CI, 25%–29%), vomiting (16%; 95% CI, 14%–17%),
and abdominal pain (11%; 95% CI, 10%–13%). The
prevalence of gastrointestinal symptoms and their distribution did not differ substantively after excluding
patients with preexisting gastrointestinal luminal and
pancreaticobiliary diseases. The overall proportion
decreased to 47% (95% CI, 44%–50%) after excluding
patients who were known to have received COVID-19
treatments that may be associated with gastrointestinal

Figure 2. Prevalence and distribution of gastrointestinal symptoms by study site.
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Figure 3. Liver test abnormalities in patients hospitalized with coronavirus disease 2019 (COVID-19), at admission and at any
time during hospitalization. Proportions were calculated using the full cohort as the denominator (N ¼ 1992). Alk phos, alkaline
phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; IQR, interquartile range; TB, total bilirubin.

side effects, such as hydroxychloroquine or remdesivir
(Supplementary material). The prevalence of gastrointestinal symptoms varied across sites (Figure 2).
Gastrointestinal symptoms preceded other COVID-19
symptoms in 13% of cases, started concurrently in 44%,
and followed the other COVID-19 symptoms in 42%. In 7
patients (0.4%), gastrointestinal symptoms were the
only manifestation of COVID-19.
In total, 74% of patients (781 of 1052) with gastrointestinal symptoms were judged to have mild symptoms
according to our criteria. Among the 271 patients with
moderate–severe symptoms, 21% had diarrhea with
more than 4 bowel movements per 24 hours, 2% had
bloody diarrhea, 18% had gastrointestinal hemorrhage,
63% underwent an abdominal computed tomography
scan (159 patients) and/or endoscopic examination (19
patients), and 23% were evaluated by the gastroenterology consult service. Gastrointestinal symptoms were
judged to be less prominent than other COVID-19
symptoms in 73% of patients, equally prominent in
20% of patients, and more prominent in 6% of patients.

Prevalence, Spectrum, and Severity of Liver
Test Abnormalities
Liver tests were available in 1712 patients (86%) at
presentation. At the time of admission, 554 patients
(28% of the full cohort; 95% CI, 26%–30%) had at least
1 abnormal liver test (Figure 2). Of these, 215 (11%;
95% CI, 11%–14%) had an abnormal ALT or TB test
result. Among patients with an abnormal ALT or TB test
result, 77% (95% CI, 71%–82%) had a mild increase,
17% (95% CI, 12%–22%) had a moderate increase, and
6% (95% CI, 3%–9%) had a severe increase. The median
abnormal liver test values are presented in Figure 3.
Liver tests were available in 1890 patients (95%) at
any time during hospitalization. Among patients with
normal liver tests at admission, 548 patients developed
at least 1 abnormality during their hospitalization; of

these, 480 (24%; 95% CI, 22%–26%) developed an
abnormal ALT or TB test result. In total, 695 (35%, 95%
CI, 33%–37%) had an increased ALT or TB test result;
56% (95% CI, 52%–59%) of these had a mild increase,
22% (95% CI, 18%–25%) had a moderate increase, and
23% (95% CI, 19%–26%) had a severe increase. Twentythree patients (1%) developed an ALT level in excess of
1000 U/L during the hospitalization, and 5 of these
(0.3%) met criteria for severe acute liver injury. No patients had an ALT level greater than 1000 U/L at
admission. The overall proportion, pattern, and severity of
abnormal ALT or TB levels did not differ after excluding
patients with prior liver disease or those known to have
received COVID-19 treatments that can cause hepatotoxicity (Supplementary material: Supplementary Figure).

Association Between Digestive Manifestations
and Severe Coronavirus Disease 2019
Outcomes
After adjusting for potential confounders, the presence of gastrointestinal symptoms was not associated
with the primary composite end point of mechanical
ventilation and/or death (odds ratio [OR], 0.93; 95% CI,
0.76–1.15). Similarly, the presence of mild (OR, 1.05;
95% CI, 0.73–1.49), moderate (OR, 1.14; 95% CI,
0.56–2.32), or severe (OR, 1.89; 95% CI, 0.57–6.30) liver
test abnormalities on admission were not associated
with the primary end point. In the exploratory analyses,
there was no association between digestive manifestations and intensive care unit admission, the need for
vasopressor support, or hospital length of stay.

Discussion
In this large and geographically diverse cohort of
patients hospitalized with COVID-19 in North America,
53% of patients experienced at least 1 gastrointestinal
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symptom and 35% developed an abnormal ALT or TB
level at some point during their illness. The majority of
gastrointestinal symptoms and hepatic abnormalities
were mild in nature. The presence of gastrointestinal
symptoms at any time or liver test abnormalities on
admission were not associated with mechanical ventilation or death.
Although liver test abnormalities are objective, the
assessment of gastrointestinal manifestations in COVID-19 is
limited by uncertainties in symptom attribution and ascertainment. In this study, we considered any symptom without a
clear alternative explanation (eg, abdominal pain resulting
from a known postoperative complication) as potentially
attributable to COVID-19. This approach likely overestimated
prevalence because some symptoms may have been related to
other factors such as medication effect (eg, diarrhea or nausea)
or critical illness (eg, gastrointestinal hemorrhage or
dysphagia). Indeed, a subgroup analysis that excluded patients
who were documented to have received COVID-19 treatments
that could cause digestive side effects showed a small decrease
in the prevalence of gastrointestinal symptoms (47%; 95% CI,
44%–50% vs 53%; 95% CI, 51%–55% overall). Similarly, a
manual review of endoscopy cases showed that approximately
half were performed to address events related to critical illness
(eg, feeding tube placement) rather than direct viral injury
(data not shown). Conversely, because the focus of care in
hospitalized patients with COVID-19 is typically the pulmonary
process, it is possible that gastrointestinal symptoms were
under-reported and/or underdocumented. Along these lines,
abdominal imaging and endoscopy—criteria we used to
determine the severity of gastrointestinal symptoms in this
study—have been used judiciously during the pandemic to
minimize in-hospital exposure, perhaps underestimating the
signiﬁcance of symptoms. Nevertheless, our ﬁndings provide
valuable information on the overall burden of digestive manifestations and associated resource utilization in patients hospitalized with COVID-19, whether owing to direct viral effect,
treatment of the infection, or a consequence of related systemic illness.
The prevalence of digestive manifestations in this study
was reasonably consistent across the majority of participating institutions and in line with that observed in other
Western studies.16,17 This is in contrast to much lower
proportions of gastrointestinal symptoms reported in
studies from China.9,10 This difference may be because the
Chinese experience largely reﬂects the early phase of the
pandemic, before widespread recognition of digestive
symptoms as a frequent consequence of COVID-19. These
early studies aimed to better understand the overall
illness, whereas more recent studies from the West have
focused speciﬁcally on identifying gastrointestinal symptoms. Alternatively, variable disease expression between
patient populations as a result of genetic or epigenetic
factors or prevalent virus mutations23 may explain the
difference in proportions and deserves more attention.
The effect of digestive involvement on pulmonary and
systemic illness through gut–lung cross-talk or other unknown mechanisms is of major potential importance. For
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example, microbiome-driven interferon signatures have
been shown to suppress viral replication in the lung and
can be disrupted by gut dysbiosis in experimental models
of inﬂuenza infection.7 Moreover, the small intestine
comprises a rich immune apparatus, the dysregulation of
which by SARS-CoV-2 could potentiate or even drive systemic inﬂammatory response.8 Our ﬁndings, however, do
not support such a hypothesis given the lack of association
between gastrointestinal symptoms and overall severity of
illness. Additional research is necessary to elucidate
whether the gut–lung axis is inﬂuential in this disease independent of gastrointestinal symptoms.
Our ﬁndings are consistent with prior reports showing
that liver test abnormalities are common in COVID-19.
Fifty-ﬁve percent of patients in this cohort had an
increased liver test at some point during their illness,
including many with abnormal aminotransferase levels,
raising the possibility of hepatocyte injury resulting from
SARS-CoV-2. However, the large majority of patients had
ALT or TB levels less than 5 times the upper limit of
normal and only 23 patients had an ALT level greater than
1000 U/L, which was not present at the time of presentation, suggesting that clinically important liver injury in
COVID-19 is uncommon. Future mechanistic investigations
will be necessary to better understand whether infection
leads to direct hepatic injury.
The ﬁndings of this study should be interpreted in the
context of several limitations, some of which are inherent
to observational research on COVID-19. As highlighted
earlier, symptom attribution and ascertainment were
inﬂuenced by several factors related to conducting
research during a pandemic, such as retrospective data
collection and reliance on medical records review rather
than direct patient interviews. Furthermore, validated
deﬁnitions for gastrointestinal symptom severity in
COVID-19 are not available and thus we devised criteria
that we believe reasonably reﬂects disease severity in
terms of patient suffering and resource utilization. Alternative deﬁnitions of severity may have led to varying interpretations of the ﬁndings. Some of these limitations are
mitigated by the large and geographically diverse sample,
highly systematic approach to patient selection, and
multilayered and rigorous strategy to ensure the veracity
of collected data. It is also important to consider that this
study was restricted to hospitalized patients and thus
does not reﬂect the prevalence and signiﬁcance of digestive manifestations in outpatients with COVID-19.
In summary, among patients hospitalized with
COVID-19, gastrointestinal symptoms and liver test abnormalities were common, but the majority were mild in
nature and their presence was not associated with worse
clinical outcomes.

Supplementary Material
Note: To access the supplementary material accompanying this article, visit the online version of Clinical
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Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2020.09.041.
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Supplementary Figure 1. Prevalence and distribution of gastrointestinal symptoms in 1860 patients without pre-existing
luminal gastrointestinal or pancreaticobiliary disease, compared with the full cohort.

Supplementary Figure 2. Prevalence and distribution of gastrointestinal symptoms in 875 patients who were not known to
have received any of the following medications that are associated with potential gastrointestinal side effects: hydroxychloroquine, chloroquine, remdesivir, oseltamivir, lopinavir/ritonavir, and interferon alpha, compared with the full cohort.
COVID-19, coronavirus disease 2019.
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Supplementary Figure 3. Prevalence and distribution of liver test abnormalities in 1876 patients without pre-existing liver
disease, compared with the full cohort. ALT, alanine aminotransferase; TB, total bilirubin.

Supplementary Figure 4. Prevalence and distribution of abnormal liver tests in 1825 patients who were not known to have
received any of the following medications with potential hepatotoxicity: remdesivir, oseltamivir, lopinavir/ritonavir, and interferon alpha, compared with the full cohort. ALT, alanine aminotransferase; COVID-19, coronavirus disease 2019; TB, total
bilirubin.
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Supplementary Table 1. Potential Covariates That Were Considered for the Primary Regression Analysis
Mechanical ventilation
or death (n ¼ 760)

No mechanical ventilation
or death (n ¼ 1232)

P value

64.1 (15.1)

57.6 (16.5)

<.0001

Male

464 (61.1)

664 (53.9)

.0017

Female

296 (38.9)

568 (46.1)

American Indian/
Alaska Native

2 (0.3)

3 (0.2)

Age, y, mean (SD)
Sex, n (%)

Race, n (%)

Asian

Cigarette smoking
status, n (%)

Alcoholism, n (%)

327 (43)

515 (41.8)

White

281 (37)

451 (36.6)

Multiple

3 (0.4)

7 (0.6)

Unknown

112 (14.7)

220 (17.9)

Current/ex-smoker

306 (40.3)

389 (31.6)

Nonsmoker

383 (50.4)

792 (64.3)

Unknown

71 (9.3)

51 (4.1)

Current/prior

93 (12.2)

178 (14.4)

547 (72)

953 (77.4)

Unknown

120 (15.8)

101 (8.2)

No

381 (50.1)

643 (52.2)

Yes

379 (49.9)

589 (47.8)

31.8 (8.9)

31.3 (8.2)

No

226 (29.7)

521 (42.3)

Yes

534 (70.3)

711 (57.7)

Body mass index,
mean (SD)
Hypertension, n (%)

Diabetes, n (%)

Cardiac disease, n (%)

Pulmonary disease, n (%)

Immunocompromised, n (%)

Active/current malignancy,
excluding nonmelanoma
skin cancer, n (%)

Moderate to severe
kidney disease
(creatinine >3 mg/dL
before admission,
end-stage
renal disease,
or dialysis), n (%)

35 (2.8)

Black/African
American

No

Obesity, n (%)

35 (4.6)

.1938

No

448 (58.9)

822 (66.7)

Yes

312 (41.1)

410 (33.3)

No

557 (73.3)

1000 (81.2)

Yes

203 (26.7)

232 (18.8)

No

591 (77.8)

987 (80.1)

Yes

169 (22.2)

245 (19.9)

No

645 (84.9)

1082 (87.8)

Yes

115 (15.1)

150 (12.2)

No

704 (92.6)

1165 (94.6)

Yes

56 (7.4)

67 (5.4)

No

663 (87.2)

1141 (92.6)

Yes

97 (12.8)

91 (7.4)

<.0001

<.0001

.3715

.2681
<.0001

.0005

<.0001

.2091

.0591

.0821

<.0001

July 2021

Digestive Manifestations in COVID-19 1365.e4

Supplementary Table 1. Continued

Luminal gastrointestinal
disease, n (%)

Chronic liver
disease, n (%)

Recent (within
1 month of
admission) or
current (at
admission) ACE
or ARB use, n (%)

Mechanical ventilation
or death (n ¼ 760)

No mechanical ventilation
or death (n ¼ 1232)

No

740 (97.4)

1168 (94.8)

Yes

20 (2.6)

64 (5.2)

No

737 (97)

1200 (97.4)

Yes

23 (3)

32 (2.6)

Yes

232 (30.5)

364 (29.5)

No

501 (65.9)

854 (69.3)

Unknown
Recent (within
1 month of
admission) or
current (at admission)
NSAIDs use, n (%)

Recent (within
1 month of
admission) or
current (at admission)
PPI or H2
blocker use, n (%)

Recent (within
1 month of
admission) or
current (at admission)
antibiotic use, n (%)

27 (3.6)

P value
.0057

.5704

.0008

14 (1.1)

Yes

190 (25)

337 (27.4)

No

425 (55.9)

718 (58.3)

Unknown

145 (19.1)

177 (14.4)

Yes

235 (30.9)

317 (25.7)

No

451 (59.3)

860 (69.8)

Unknown

74 (9.7)

55 (4.5)

Yes

241 (31.7)

346 (28.1)

No

472 (62.1)

852 (69.2)

Unknown

47 (6.2)

34 (2.8)

.0193

<.0001

<.0001

ACE, Angiotensin converting enzyme; ARB, Angiotensin Receptor Blocker; H2, Histamine 2; NSAID, nonsteroidal anti-inﬂammatory drug; PPI, proton pump
inhibitor.

